NO312809B1 - Fremgangsmåter for fremstilling av en farmasöytisk sammensetning ved anvendelse av unilamell¶re liposomalearachidonsyremetabolitt formuleringer samt anvendelse derav - Google Patents

Fremgangsmåter for fremstilling av en farmasöytisk sammensetning ved anvendelse av unilamell¶re liposomalearachidonsyremetabolitt formuleringer samt anvendelse derav Download PDF

Info

Publication number: NO312809B1
Authority: NO; Norway
Prior art keywords: metabolite; lipid; disease; liposomes; animal
Prior art date: 1993-11-04

Application number

NO19961778A

Other languages

English (en)

Norwegian (no)

Other versions

NO961778L (no

NO961778D0 (no

Inventor

Marc J Ostro

Andrew Stuart Janoff

Sharma R Minchey

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-04

Filing date

1996-05-02

Publication date

2002-07-08

1996-05-02 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1996-05-02 Publication of NO961778D0 publication Critical patent/NO961778D0/no

1996-06-25 Publication of NO961778L publication Critical patent/NO961778L/no

2002-07-08 Publication of NO312809B1 publication Critical patent/NO312809B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 31
238000009472 formulation Methods 0.000 title claims abstract description 17
238000000034 method Methods 0.000 title claims description 65
239000002207 metabolite Substances 0.000 title claims description 41
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
239000002253 acid Substances 0.000 title claims description 3
241001465754 Metazoa Species 0.000 claims abstract description 58
150000003180 prostaglandins Chemical class 0.000 claims abstract description 48
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
150000002632 lipids Chemical class 0.000 claims abstract description 35
206010061218 Inflammation Diseases 0.000 claims abstract description 20
230000004054 inflammatory process Effects 0.000 claims abstract description 20
239000000872 buffer Substances 0.000 claims abstract description 19
230000002401 inhibitory effect Effects 0.000 claims abstract description 17
201000010099 disease Diseases 0.000 claims abstract description 16
206010004053 Bacterial toxaemia Diseases 0.000 claims abstract description 11
208000013222 Toxemia Diseases 0.000 claims abstract description 9
238000011282 treatment Methods 0.000 claims description 24
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 16
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 16
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 16
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 16
230000006378 damage Effects 0.000 claims description 16
230000037396 body weight Effects 0.000 claims description 14
208000014674 injury Diseases 0.000 claims description 14
230000020411 cell activation Effects 0.000 claims description 13
239000002691 unilamellar liposome Substances 0.000 claims description 13
230000021164 cell adhesion Effects 0.000 claims description 12
239000012062 aqueous buffer Substances 0.000 claims description 10
150000001720 carbohydrates Chemical group 0.000 claims description 10
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 9
125000002252 acyl group Chemical group 0.000 claims description 9
239000012867 bioactive agent Substances 0.000 claims description 9
238000001035 drying Methods 0.000 claims description 9
208000010125 myocardial infarction Diseases 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 8
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 8
208000027418 Wounds and injury Diseases 0.000 claims description 8
230000003993 interaction Effects 0.000 claims description 8
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
239000008121 dextrose Substances 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
201000005569 Gout Diseases 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
206010003246 arthritis Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
239000011814 protection agent Substances 0.000 claims description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
206010044541 Traumatic shock Diseases 0.000 claims description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
206010047115 Vasculitis Diseases 0.000 claims description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
230000002917 arthritic effect Effects 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
125000003071 maltose group Chemical group 0.000 claims description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
208000025865 Ulcer Diseases 0.000 claims 1
230000009429 distress Effects 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
231100000397 ulcer Toxicity 0.000 claims 1
239000002502 liposome Substances 0.000 abstract description 103
208000035475 disorder Diseases 0.000 abstract description 23
229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 20
229960000711 alprostadil Drugs 0.000 abstract description 19
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract description 13
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract description 12
230000004913 activation Effects 0.000 abstract description 5
230000001413 cellular effect Effects 0.000 abstract description 4
230000001668 ameliorated effect Effects 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
239000002158 endotoxin Substances 0.000 description 38
229920006008 lipopolysaccharide Polymers 0.000 description 34
210000004072 lung Anatomy 0.000 description 26
210000002216 heart Anatomy 0.000 description 20
102000000589 Interleukin-1 Human genes 0.000 description 19
108010002352 Interleukin-1 Proteins 0.000 description 19
210000000440 neutrophil Anatomy 0.000 description 19
241000282472 Canis lupus familiaris Species 0.000 description 18
210000004027 cell Anatomy 0.000 description 18
241000700159 Rattus Species 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
239000011780 sodium chloride Chemical class 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
239000000902 placebo Substances 0.000 description 14
229940068196 placebo Drugs 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
238000001802 infusion Methods 0.000 description 11
230000010410 reperfusion Effects 0.000 description 11
238000012360 testing method Methods 0.000 description 11
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 10
206010061216 Infarction Diseases 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 10
239000003814 drug Substances 0.000 description 10
230000007574 infarction Effects 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
230000017531 blood circulation Effects 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000004005 microsphere Substances 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
210000002889 endothelial cell Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000001125 extrusion Methods 0.000 description 7
208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
108010088751 Albumins Proteins 0.000 description 6
102000009027 Albumins Human genes 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
238000002399 angioplasty Methods 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
239000010432 diamond Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
230000008733 trauma Effects 0.000 description 6
239000004322 Butylated hydroxytoluene Substances 0.000 description 5
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
108010023197 Streptokinase Proteins 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229940095259 butylated hydroxytoluene Drugs 0.000 description 5
235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
239000000969 carrier Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000003755 preservative agent Substances 0.000 description 5
208000037803 restenosis Diseases 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
229960005202 streptokinase Drugs 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000037487 Endotoxemia Diseases 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 4
239000000232 Lipid Bilayer Substances 0.000 description 4
208000001871 Tachycardia Diseases 0.000 description 4
206010000891 acute myocardial infarction Diseases 0.000 description 4
229940114079 arachidonic acid Drugs 0.000 description 4
235000021342 arachidonic acid Nutrition 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
230000018044 dehydration Effects 0.000 description 4
238000006297 dehydration reaction Methods 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
230000000302 ischemic effect Effects 0.000 description 4
239000004816 latex Substances 0.000 description 4
229920000126 latex Polymers 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000011148 porous material Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
230000006794 tachycardia Effects 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
102000003896 Myeloperoxidases Human genes 0.000 description 3
108090000235 Myeloperoxidases Proteins 0.000 description 3
206010038563 Reocclusion Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000036765 blood level Effects 0.000 description 3
230000004087 circulation Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
230000009849 deactivation Effects 0.000 description 3
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
210000003989 endothelium vascular Anatomy 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000003925 fat Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000004941 influx Effects 0.000 description 3
230000005732 intercellular adhesion Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
150000002617 leukotrienes Chemical class 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000013222 sprague-dawley male rat Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
206010003504 Aspiration Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010058490 Hyperoxia Diseases 0.000 description 2
102000003777 Interleukin-1 beta Human genes 0.000 description 2
108090000193 Interleukin-1 beta Proteins 0.000 description 2
-1 LUV Substances 0.000 description 2
208000004852 Lung Injury Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
206010069363 Traumatic lung injury Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
108010031318 Vitronectin Proteins 0.000 description 2
102100035140 Vitronectin Human genes 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003413 degradative effect Effects 0.000 description 2
238000002296 dynamic light scattering Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
235000004626 essential fatty acids Nutrition 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000000222 hyperoxic effect Effects 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000003960 inflammatory cascade Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
231100000516 lung damage Toxicity 0.000 description 2
231100000515 lung injury Toxicity 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000010926 purge Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100039065 Interleukin-1 beta Human genes 0.000 description 1
229930184725 Lipoxin Natural products 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
241000002163 Mesapamea fractilinea Species 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000002022 anti-cellular effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001384 anti-glaucoma Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000017455 cell-cell adhesion Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940108488 droperidol / fentanyl Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
208000027096 gram-negative bacterial infections Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002639 lipoxins Chemical class 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000024717 negative regulation of secretion Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
239000002331 radioactive microsphere Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Dispersion Chemistry (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Saccharide Compounds (AREA)
Detergent Compositions (AREA)

NO19961778A 1993-11-04 1996-05-02 Fremgangsmåter for fremstilling av en farmasöytisk sammensetning ved anvendelse av unilamell¶re liposomalearachidonsyremetabolitt formuleringer samt anvendelse derav NO312809B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US14789893A	1993-11-04	1993-11-04
US15285293A	1993-11-16	1993-11-16
US18008994A	1994-01-11	1994-01-11
PCT/US1994/012579 WO1995012388A1 (en)	1993-11-04	1994-11-03	Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations

Publications (3)

Publication Number	Publication Date
NO961778D0 NO961778D0 (no)	1996-05-02
NO961778L NO961778L (no)	1996-06-25
NO312809B1 true NO312809B1 (no)	2002-07-08

Family

ID=27386612

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19961778A NO312809B1 (no)	1993-11-04	1996-05-02	Fremgangsmåter for fremstilling av en farmasöytisk sammensetning ved anvendelse av unilamell¶re liposomalearachidonsyremetabolitt formuleringer samt anvendelse derav
NO19961779A NO312810B1 (no)	1993-11-04	1996-05-02	Multilamell¶r liposomal arachidonsyre metabolitt formuleringer og en fremgangsmåte for fremstilling av etmedikament derav

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO19961779A NO312810B1 (no)	1993-11-04	1996-05-02	Multilamell¶r liposomal arachidonsyre metabolitt formuleringer og en fremgangsmåte for fremstilling av etmedikament derav

Country Status (13)

Country	Link
EP (2)	EP0726763B1 (de)
JP (2)	JPH09504793A (de)
KR (2)	KR100355246B1 (de)
AT (2)	ATE191141T1 (de)
AU (2)	AU687921B2 (de)
CA (2)	CA2175896A1 (de)
DE (2)	DE69423773T2 (de)
DK (2)	DK0726763T3 (de)
ES (2)	ES2144118T3 (de)
GR (2)	GR3032006T3 (de)
NO (2)	NO312809B1 (de)
PT (1)	PT726763E (de)
WO (2)	WO1995012388A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2179986A1 (en) *	1994-01-11	1995-07-13	Andrew S. Janoff	Treatment using arachidonic acid metabolite and particulate formulations
CA2260859A1 (en) *	1996-07-22	1998-01-29	Monsanto Company	Thiol sulfone metalloprotease inhibitors
US6747027B1 (en)	1996-07-22	2004-06-08	Pharmacia Corporation	Thiol sulfonamide metalloprotease inhibitors
US6362183B1 (en)	1997-03-04	2002-03-26	G. D. Searle & Company	Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en)	1997-03-04	1998-09-11	Monsanto Company	N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en)	1997-03-04	1998-09-11	Monsanto Company	Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US20010039287A1 (en)	1997-11-14	2001-11-08	Thomas E Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en)	1997-11-14	2004-06-15	Pharmacia Corporation	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2001523662A (ja)	1997-11-14	2001-11-27	ジー・ディー・サール・アンド・カンパニー	芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
AP2001002240A0 (en)	1999-02-08	2001-09-30	Searle & Co	Sufamato hydroxamic acid metalloprotease inhibitor.
US6583299B1 (en)	1999-05-20	2003-06-24	G.D. Searle & Co.	α-amino-β-sulfonyl hydroxamic acid compounds
US6683078B2 (en)	2001-07-19	2004-01-27	Pharmacia Corporation	Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
JP2003342196A (ja) *	2002-05-31	2003-12-03	Mukku:Kk	静脈注射用組成物、その製造法およびその製剤
WO2013039851A1 (en)	2011-09-12	2013-03-21	Mallinckrodt Llc	Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN111053743B (zh) *	2018-10-16	2023-07-14	石药集团中奇制药技术（石家庄）有限公司	一种前列地尔脂质体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988009170A1 (en) *	1987-05-22	1988-12-01	The Liposome Company, Inc.	Prostaglandin-lipid formulations
US5262168A (en) *	1987-05-22	1993-11-16	The Liposome Company, Inc.	Prostaglandin-lipid formulations
JPH0395118A (ja) *	1989-09-07	1991-04-19	Green Cross Corp:The	プロスタグランジン含有脂肪小体製剤
JPH04356421A (ja) *	1991-03-06	1992-12-10	Green Cross Corp:The	プロスタグランジン類含有脂肪小体組成物
ATE176401T1 (de) *	1991-05-07	1999-02-15	Liposome Co Inc	Liposomale prostaglandinformulierungen
JPH05139977A (ja) *	1991-05-17	1993-06-08	Green Cross Corp:The	プロスタグランジン類リポソーム複合体を充填した注射器

1994
- 1994-11-03 EP EP95900504A patent/EP0726763B1/de not_active Expired - Lifetime
- 1994-11-03 JP JP7513436A patent/JPH09504793A/ja not_active Abandoned
- 1994-11-03 AU AU81326/94A patent/AU687921B2/en not_active Ceased
- 1994-11-03 AT AT95900504T patent/ATE191141T1/de not_active IP Right Cessation
- 1994-11-03 DE DE69423773T patent/DE69423773T2/de not_active Expired - Fee Related
- 1994-11-03 JP JP7513378A patent/JPH09511216A/ja active Pending
- 1994-11-03 ES ES95900504T patent/ES2144118T3/es not_active Expired - Lifetime
- 1994-11-03 DK DK95900504T patent/DK0726763T3/da active
- 1994-11-03 DK DK95900532T patent/DK0726764T3/da active
- 1994-11-03 CA CA002175896A patent/CA2175896A1/en not_active Abandoned
- 1994-11-03 WO PCT/US1994/012579 patent/WO1995012388A1/en not_active Ceased
- 1994-11-03 PT PT95900504T patent/PT726763E/pt unknown
- 1994-11-03 DE DE69420859T patent/DE69420859T2/de not_active Expired - Fee Related
- 1994-11-03 KR KR1019960702299A patent/KR100355246B1/ko not_active Expired - Fee Related
- 1994-11-03 KR KR1019960702298A patent/KR100355247B1/ko not_active Expired - Fee Related
- 1994-11-03 AU AU81308/94A patent/AU8130894A/en not_active Abandoned
- 1994-11-03 EP EP95900532A patent/EP0726764B1/de not_active Expired - Lifetime
- 1994-11-03 ES ES95900532T patent/ES2136271T3/es not_active Expired - Lifetime
- 1994-11-03 CA CA002175057A patent/CA2175057A1/en not_active Abandoned
- 1994-11-03 AT AT95900532T patent/ATE184785T1/de not_active IP Right Cessation
- 1994-11-03 WO PCT/US1994/012710 patent/WO1995012389A1/en not_active Ceased
1996
- 1996-05-02 NO NO19961778A patent/NO312809B1/no not_active IP Right Cessation
- 1996-05-02 NO NO19961779A patent/NO312810B1/no not_active IP Right Cessation
1999
- 1999-11-30 GR GR990403099T patent/GR3032006T3/el unknown
2000
- 2000-06-29 GR GR20000401517T patent/GR3033817T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK0726763T3 (da)	2000-07-10
KR100355247B1 (ko)	2003-01-24
JPH09511216A (ja)	1997-11-11
ES2136271T3 (es)	1999-11-16
KR100355246B1 (ko)	2003-01-06
NO961779L (no)	1996-05-02
DK0726764T3 (da)	1999-12-20
DE69423773D1 (de)	2000-05-04
EP0726763A1 (de)	1996-08-21
ATE184785T1 (de)	1999-10-15
NO312810B1 (no)	2002-07-08
EP0726764A1 (de)	1996-08-21
AU8130894A (en)	1995-05-23
KR960705543A (ko)	1996-11-08
NO961778L (no)	1996-06-25
CA2175896A1 (en)	1995-05-11
GR3033817T3 (en)	2000-10-31
AU687921B2 (en)	1998-03-05
DE69420859T2 (de)	2000-01-05
EP0726764B1 (de)	1999-09-22
ATE191141T1 (de)	2000-04-15
NO961778D0 (no)	1996-05-02
CA2175057A1 (en)	1995-05-11
DE69420859D1 (de)	1999-10-28
WO1995012389A1 (en)	1995-05-11
DE69423773T2 (de)	2000-07-20
KR960705544A (ko)	1996-11-08
WO1995012388A1 (en)	1995-05-11
ES2144118T3 (es)	2000-06-01
NO961779D0 (no)	1996-05-02
PT726763E (pt)	2000-09-29
EP0726763B1 (de)	2000-03-29
JPH09504793A (ja)	1997-05-13
GR3032006T3 (en)	2000-03-31
AU8132694A (en)	1995-05-23

Legal Events

Date	Code	Title	Description
2006-07-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP0512916B1 (de)	1999-02-03	Liposomale Prostaglandinformulierungen
JP3626184B2 (ja)	2005-03-02	薬剤搬送ビヒクルとしての固体脂肪ナノエマルジョン体
US5925375A (en)	1999-07-20	Therapeutic use of multilamellar liposomal prostaglandin formulations
KR101342971B1 (ko)	2013-12-18	섬유화 억제를 위한 약물 담체 및 약물 담체 키트
EP0726763B1 (de)	2000-03-29	Behandlungsverfahren unter verwendung unilamellar-liposomaler arachiddonsäuremetabolit-formulierungen
EP1638526B1 (de)	2010-04-28	Verfahren zur behandlung von akuten koronaren syndromen
US20160206580A1 (en)	2016-07-21	Multivesicular liposome formulations of tranexamic acid
JP6231995B2 (ja)	2017-11-15	眼の疾患の合併症を低減するための薬学的組成物
US5811118A (en)	1998-09-22	Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
Das	2003	Insulin in sepsis and septic shock
JP2022514991A (ja)	2022-02-16	安定な麻酔薬製剤および関連する剤形
JP2016506920A (ja)	2016-03-07	止血組成物
US6030639A (en)	2000-02-29	Treatment using prostoglandin and particulate formulations
AU682753B2 (en)	1997-10-16	Treatment using arachidonic acid metabolite and particulate formulations
CN117100696A (zh)	2023-11-24	一种治缺血性心肌再灌注损伤的药物制剂及其应用
JPH04173736A (ja)	1992-06-22	乳化剤
JPH06256212A (ja)	1994-09-13	オーレオバシジン類のリポソーム製剤